Trial Profile
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patients: A multicenter, open-label, phase 4 clinical study
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms TASIGNA-IIT
- 25 Jan 2013 New trial record